Nicotinamide Adenine Dinucleotide

RCT supports nicotinamide riboside boost for muscle mitochondrial biogenesis

19-Jan-2023 By Stephen Daniells

Supplementation with nicotinamide riboside may improve muscle mitochondrial biogenesis, according to data from a first-of-its kind five-month-long clinical study with twins.

Cash infusion from Nestlé buoys ChromaDex as it works to get costs under control

10-Nov-2022 By Hank Schultz

A cash infusion from Nestle and an uptick in online consumer sales has buoyed ChromaDex as executives say the brand is on course to be in plus EBITDA territory by the end of fiscal 2022.

NR legal rumbles continue as USPTO board splits recent decisions on patent challenges

23-Aug-2022 By Stephen Daniells

The U.S. Patent & Trademark Office’s Patent Trial and Appeal Board’s (PTAB) recently rejected a challenge by Thorne Research, Inc. against one of the key patents covering nicotinamide riboside, coming a few months after the PTAB ruled in favor of...

ChromaDex keeps foot on sales & research pedal even as stubborn losses persist

13-May-2022 By Hank Schultz

Branded ingredient supplier ChromaDex announced an 18% sales gain in a recent earrings report. A continued push to increase the science behind its TruNiagen brand is part of the reason, the company’s co-founder said.

ChromaDex passes research program milestone with 100th Niagen study

02-Feb-2022 By Hank Schultz

ChromaDex has announced the publication of the 100th study under a research program centered on its Niagen ingredient.

Majority of NMN products tested by ChromaDex had virtually none of active ingredient

14-Jan-2022 By Hank Schultz

Supplement manufacturer ChromaDex alleges that testing has revealed that more than half of NMN anti aging supplements being sold on Amazon contained almost none of the bioactive molecule.

In communicating research results, ChromaDex runs afoul of COVID-19 watchdogs

07-Dec-2020 By Hank Schultz

The US Food and Drug Administration has issued an additional raft of warning letters on COVID-19 claims. One major industry name — ChromaDex — appeared on the list.

NR pioneer: ‘I think if we combine Niagen with exercise that we’re really going to get some place’

10-Sep-2020 By Stephen Daniells

With recent data providing “solid evidence” for nicotinamide riboside’s effects on inflammation and body composition, combining NR with exercise will see us “really get some place”, says Dr Charles Brenner.

Vitamin B3 supplementation offers ‘significant improvement’ in glaucoma patients: Study

10-Aug-2020 By Danielle Masterson

A clinical trial led by the Center for Eye Research Australia has shown that vitamin B3 (nicotinamide) shows promise for glaucoma sufferers.

Tru Niagen expands international footprint with expansion to Canada

18-Dec-2018 By Adi Menayang

Healthy aging supplement Tru Niagen, owned by California-based ChromaDex, has been approved for sale in Canada by the country’s health authority Health Canada.

Jaksch says move into chairman role part of ChromaDex's pivot toward finished goods

14-May-2018 By Hank Schultz

A strategic pivot toward finished products underpins his impending move toward an advisory role, said ChromaDex CEO Frank Jaksch.

ChromaDex raises another $23 million via private offering

07-Nov-2017 By Hank Schultz

ChromaDex is in line to receive another $23 million of investment, including from a fund associated with Facebook CEO Mark Zuckerberg, via private placement of stock.

Niagen nicotinamide riboside may reduce obesity-related inflammation

20-Nov-2015 By Stephen Daniells

Nicotinamide riboside, a vitamin B3 derivative, may reduce inflammation linked to obesity, and reduce the risk of diseases linked to this type of inflammation, according to pre-clinical data from scientists at the National Institutes of Health.

Chromadex cements position in NR market with third IP acquisition

13-Mar-2013 By Hank Schultz

Chromadex has announced a licensing deal with Washington University in St. Louis for the worldwide exclusive patent rights related to the recently discovered vitamin nicotinamide riboside (NR). It is Chromadex’s third IP acquisition related to the molecule.

GMP compliance is a 'huge opportunity' for dietary supplements market: Chromadex CEO

07-Mar-2013 By Stephen Daniells in Irvine, CA

FDA enforcement of the current good manufacturing practices (cGMP) regulations is ‘a huge opportunity for the dietary supplements market’, says Frank Jaksch, CEO of Chromadex.

ChromaDex gears up for launch of next generation niacin ingredient

17-Jul-2012 By Elaine Watson

ChromaDex is gearing up for a commercial launch of Nicotinamide riboside (NR) - a next generation version of vitamin B3 (niacin) claimed to help protect the brain, battle the bulge and improve blood glucose control - at the end of this year or early next.

ChromaDex: We’ll do for nicotinamide riboside what we did for pterostilbene

25-Jul-2011 By Elaine Watson

Nicotinamide riboside (NR) - the latest addition to ChromaDex’s bioactive ingredients stable – will follow a similar development path to pterostilbene, a compound found in blueberries it has synthesized to create a branded ingredient called pTeroPure.